CardioPharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CardioPharma is a private, pre-revenue biotech company targeting the global cardiovascular disease epidemic with its patented polypill platform. Founded in 2003 and based in San Diego, the company's strategy centers on improving medication adherence—a major issue in CVD management—by consolidating multiple essential drugs into a single, convenient daily dose. Its lead asset, CardiaPill®, is protected by a key US patent and several international grants, with a patent term extending to 2039, providing a long runway for development and commercialization. The company is led by seasoned pharmaceutical executives and is pursuing global regulatory pathways for its pipeline.

Cardiovascular Disease

Technology Platform

Patented platform for formulating fixed-dose combination polypills (combining statins, ACE inhibitors, ARBs, and anti-platelet agents) into a single daily pill to improve adherence.

Opportunities

The massive global CVD patient population and the high cost of non-adherence create a significant addressable market.

Payers and health systems are increasingly focused on cost-effective, outcomes-based solutions for chronic disease management, which aligns perfectly with the polypill's value proposition.

Risk Factors

The regulatory pathway for a fixed-dose combination product is complex and uncertain.

Commercial success depends on overcoming physician prescribing habits for individual generics and securing favorable reimbursement from payers who may be skeptical of a branded product containing generic components.

Competitive Landscape

The competitive landscape includes other companies developing cardiovascular polypills (e.g., Ferrer Internacional, Dr. Reddy's Laboratories with Polycap), as well as the entrenched standard of care: separate prescriptions for generic statins, antihypertensives, and antiplatelets. CardioPharma's differentiation lies in its specific patented formulations and its focus on a triple-therapy combination.

More companies in Drug Delivery & Formulation →More companies in United States →